Catalyst Pharmaceuticals (CPRX) Tops Q3 EPS by 27c, provides guidance

Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q3 EPS of $0.57, $0.27 better than the analyst estimate of $0.30. Revenue for the quarter came in at $128.7 million versus the consensus estimate of $123.41 million.

GUIDANCE:

Catalyst Pharmaceuticals sees FY2024 revenue of $475-485 million, versus the consensus of $473.7 million.

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.

You May Also Be Interested In

• FDA approves Revolution Medicines pancreatic cancer drug Rasonque
• Dycom Industries (DY) Tops Q2 EPS by 59c, Beats on Revenue
• nCino, Inc. (NCNO) Reports Q2 EPS of $0.05, Offers Guidance